|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that LOAd713 can kill infected tumor cells and has the capacity to affect the tumor microenvironment by stimulating stellate cells and myeloid suppressors with TMZ-CD40L and IL-6R blockade.
|
30617223 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK) suicide gene therapy and exogenous CD40 ligand (CD40L)-CD40 interaction in cancer via conditionally replicating adenovirus can selectively kill tumors without damaging normal tissues.
|
30848201 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutic treatment with rMVA-CD40L-expressing tumor-associated antigens results in the control of established tumors.
|
31695037 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed that CD40L<sup>+</sup> CAR T cells circumvent tumor immune escape via antigen loss through CD40/CD40L-mediated cytotoxicity and induction of a sustained, endogenous immune response.
|
30889381 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adenoviral-mediated expression of CD40 ligand (CD40L) on dendritic cells (DCs) activates immune check point CD40/CD40L, enhancing the immunostimulation of DCs and effector cells against human renal carcinoma cells (RCC) and inducing tumor cell apoptosis in vitro.
|
31519562 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we use fully serotype 3 oncolytic adenovirus Ad3-hTERT-CMV-hCD40L, expressing human CD40L, to modulate the tumor microenvironment with subsequently improved function of DCs.
|
30386680 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mechanisms linking the CD40/CD40L system and the soluble form of CD40 ligand (sCD40L) with neoplasia are nowadays a topic of intensive research.
|
29715163 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, we studied a membrane‑stable mutant form CD40L (CD40L‑M) to explore tumor growth and cellular senescence in CD40‑positive NSCLC cells.
|
29565449 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD40L/interleukin-4 (IL-4) stimulation occurs in vivo in the tumor microenvironment and induces global translation to varying degrees in individuals with chronic lymphocytic leukemia (CLL) in vitro.
|
30082430 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, Trop‑2‑CD40L VLP immunization increased the survival rate of Lewis tumor‑bearing mice more significantly when compared with Trop‑2 only VLPs.
|
29568866 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the highest tumor uptake was found for <sup>68</sup>Ga-FSC-(RGD)<sub>3</sub> and <sup>68</sup>Ga-THP-(RGD)<sub>3</sub> in the SK-RC-52 and FaDu models, respectively, selection of the optimal tracer for specific diagnostic applications also depends on tumor-to-blood ratio and uptake in normal tissues; these factors should therefore also be considered.
|
29626124 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, CD40L-mediated gene therapy is an interesting concept for the treatment of tumors with high levels of M2 macrophages, such as pancreatic cancer, and an oncolytic virus as carrier of CD40L may further boost tumor killing and immune activation.
|
27906162 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Triple combination of ISF35, anti-PD-1, and anti-CTLA-4 results in complete eradication of injected and noninjected subcutaneous tumors, as well as melanoma tumors in the brain.
|
29129918 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, high expression of AHRR was associated with high expression of CD40 in tumor cells, with CD40L expression being particularly high in the tumor interstitium.
|
27262846 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have generated a replication incompetent CD40 ligand-expressing recombinant vaccinia virus (rVV40L) to promote the differentiation of human naïve CD8(+) T cells into TCM specific for viral and tumor-associated antigens.
|
26561341 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.
|
25382101 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, combination therapy using Flt3L to induce DC proliferation and CD40L to enhance DC maturation holds great promise for immunomodulation of radiation therapy to enhance HCC tumor control and prevent progression of disease in patients with diffuse HCC.
|
24992166 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, up-regulated expressions of CD40LG and IRF7 may make for improved tumor cytolytic function of CIK(IL-2) through type I interferon signaling.
|
25108500 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
|
24305418 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas MB49 cells implanted into immunocompetent mice responded poorly to RAd-CD40L or 5-FU alone, administration of both agents dramatically decreased tumor growth, increased survival of the mice and induced systemic MB49-specific immunity.
|
24357147 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Through a bystander mechanism of intercellular transfer of CD40L from the donor NSCs to tumor target cells, the treatment impeded tumor growth, leading to prolonged survival of the tumor-bearing mice.
|
24773154 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.
|
23994887 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we show that the CD40 and CD40-L expressions on monocytes and T cells, respectively, decrease as the head and neck squamous cell carcinoma (HNSCC) patients progress from stage-I through stage-IV suggesting a novel CD40/CD40-L expression based staging of HNSCC tumor.
|
23000501 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ad5/3-hTERT-E1A-hCD40L significantly inhibited tumor growth in vivo via oncolytic and apoptotic effects, and (Ad5/3-hTERT-E1A-hCD40L)-mediated oncolysis resulted in enhanced calreticulin exposure and HMGB1 and ATP release, which were suggestive of immunogenicity.
|
22396493 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.
|
22402624 |
2012 |